Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Adimab: platform transfer agreement; WuXi Biologics: cell line license
Indications
COVID-19 prevention(Phase 3)
Catalysts
— Later Q3 2026
— Later Q3 2026
Status note REVOLUTION program includes three trials: DECLARATION (Phase 3 prevention, enrollment completed June 2026, supports potential BLA), LIBERTY (Phase 3 vs mRNA vaccine, fully dosed), and DRUMMER (pediatric, to be actioned only if DECLARATION succeeds). Fast Track designation for COVID-19 prevention.
COVID-19 pre-exposure prophylaxis (immunocompromised)(Stage not disclosed)
Catalysts
— June 29, 2027
Status note Authorized under EUA since March 22, 2024. Company in dialogue with FDA on next steps following EUA termination.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.